-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Xcelerate, Inc. Expands IP with Acquisition of Patent Portfolio
Xcelerate, Inc. Expands IP with Acquisition of Patent Portfolio
MAULDIN, SC / ACCESSWIRE / May 4, 2022 / Xcelerate, Inc. (OTC PINK:XCRT) today announced that it signed a purchase agreement to acquire a portfolio of patents, patents pending and technology licenses from HS Pharmaceuticals LLC, a manufacturer and distributer of dermatological products for chronic wounds, burns and drug resistant infections.
"As many of our shareholders know, this acquisition is the culmination of discussions started nearly two years ago with HS Pharmaceuticals and greatly enhances XCRT's mission of acquiring innovation at the engineering/patent level and developing it for commercialization," said Xcelerate CEO Michael O'Shea. "HS Pharmaceuticals has been shepherding these patents for the last 10+ years in conjunction with world renowned scientists and universities and we are excited to take this amazing intellectual property to the next level."
The portfolio consists of four issued and one pending U.S. patents, two issued and one pending European patent, as well as certain licensing agreements in conjunction with research developed by Cambridge University.
U.S. Patents
- U.S. 9,889,151: methods of treating specific cancers with a composition releasing orthosilicic acid in vivo
- U.S. 9,333,224: methods of treating bacterial infection with a composition releasing orthosilicic acid in vivo
- U.S. 10,493,097: methods of treating specific types of ulcers (wounds) with a composition releasing orthosilicic acid in vivo
- U.S. 16/089,613: composition for bone repair/replacement comprising silicate and bone/bone surrogate
- U.S. 16/670,060 pending
European Patents - Validated in Germany, Spain, France, the United Kingdom, Ireland, Italy
- EP 2211868: Silicate solution for treating melanoma
- EP 3305305: Silicate solution for wound healing
- EP 21178277.6 pending
- In-licensed IP (United Kingdom Research and Innovation)
- Granted U.S., EP, AU, JP, Eurasian, CN patents
- Pending in CA, HK, KR, SG
The acquisition of this new patent portfolio represents the culmination of years of research by world renowned scientists and institutions as well as millions of dollars in development costs and further enhances the Company's existing patent and technology base. Xcelerate has issued 10 million shares of its' restricted common stock to HS Pharmaceuticals for these assets. The relevant agreement also provides for a profit-sharing arrangement based on future earnings of the assets as well as providing a Board seat for one of HS Pharmaceuticals members.
About Xcelerate, Inc.
Xcelerate is a start-up, development stage company that has assembled an Advisory Board of internationally renowned translational clinicians and engineers to assist the Company in identifying and acquiring cutting-edge engineering technological advancements and intellectual property, most of which does not have immediately obvious applications to medical technology and clinical care. The Company goal is to acquire innovation at the engineering/patent level and develop med tech and clinical care applications.
Xcelerate has also recently acquired a 51% ownership interest in AfiyaSasa Africa, LLC a start-up medical technology and virtual health company, recently founded by Dr. Dilan Ellegala and Doyle Word. This technology is centered around patented and patent pending software that uses and incorporates artificial intelligence ("AI") and Augmented Reality ("AR") licensed from AdviNOW.
For more information, visit the company's website at
SAFE HARBOR
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and actual results may differ materially from those projected in forward-looking statements resulting from various factors.
Xcelerate Contact
Info@Xcelerate.Global
SOURCE: Xcelerate, Inc.
View source version on accesswire.com:
MAULDIN, SC / ACCESSWIRE / May 4, 2022 / Xcelerate, Inc. (OTC PINK:XCRT) today announced that it signed a purchase agreement to acquire a portfolio of patents, patents pending and technology licenses from HS Pharmaceuticals LLC, a manufacturer and distributer of dermatological products for chronic wounds, burns and drug resistant infections.
南卡罗来纳州莫尔丁/ACCESSWIRE/2022年5月4日/Xcelerate公司(场外粉色:XCRT)今天宣布,它签署了一项购买协议,从HS PharmPharmticals LLC收购了一系列专利、正在申请的专利和技术许可,HS PharmPharmticals LLC是一家生产和分销治疗慢性伤口、烧伤和耐药感染的皮肤科产品的公司。
"As many of our shareholders know, this acquisition is the culmination of discussions started nearly two years ago with HS Pharmaceuticals and greatly enhances XCRT's mission of acquiring innovation at the engineering/patent level and developing it for commercialization," said Xcelerate CEO Michael O'Shea. "HS Pharmaceuticals has been shepherding these patents for the last 10+ years in conjunction with world renowned scientists and universities and we are excited to take this amazing intellectual property to the next level."
Xcelerate首席执行官Michael O‘Shea说:“正如我们的许多股东所知道的那样,这次收购是近两年前与HS制药公司开始的谈判的高潮,极大地增强了XCRT在工程/专利层面获得创新并将其开发成商业化的使命。”在过去的10多年里,HS制药公司一直在与世界知名的科学家和大学一起管理这些专利,我们很高兴能将这一令人惊叹的知识产权提升到一个新的水平。“
The portfolio consists of four issued and one pending U.S. patents, two issued and one pending European patent, as well as certain licensing agreements in conjunction with research developed by Cambridge University.
该投资组合包括四项已发布和一项未决的美国专利,两项已发布和一项未决的欧洲专利,以及与剑桥大学开发的研究相关的某些许可协议。
U.S. Patents
美国专利
- U.S. 9,889,151: methods of treating specific cancers with a composition releasing orthosilicic acid in vivo
- U.S. 9,333,224: methods of treating bacterial infection with a composition releasing orthosilicic acid in vivo
- U.S. 10,493,097: methods of treating specific types of ulcers (wounds) with a composition releasing orthosilicic acid in vivo
- U.S. 16/089,613: composition for bone repair/replacement comprising silicate and bone/bone surrogate
- U.S. 16/670,060 pending
- 美国9,889,151:体内释放原硅酸组合物治疗特定癌症的方法
- 美国9,333,224:体内释放原硅酸组合物治疗细菌感染的方法
- 美国10,493,097:体内释放原硅酸组合物治疗特定类型溃疡(伤口)的方法
- 美国16/089,613:含有硅酸盐和骨/骨替代物的骨修复/替代组合物
- 美国16/670,060待定
European Patents - Validated in Germany, Spain, France, the United Kingdom, Ireland, Italy
欧洲专利-在德国、西班牙、法国、英国、爱尔兰、意大利验证
- EP 2211868: Silicate solution for treating melanoma
- EP 3305305: Silicate solution for wound healing
- EP 21178277.6 pending
- In-licensed IP (United Kingdom Research and Innovation)
- Granted U.S., EP, AU, JP, Eurasian, CN patents
- Pending in CA, HK, KR, SG
- EP 2211868:治疗黑色素瘤的硅酸盐溶液
- EP 3305305:用于伤口愈合的硅酸盐溶液
- EP 21178277.6待定
- 授权内知识产权(英国研究与创新)
- 已授予美国、EP、AU、JP、欧亚、CN专利
- 在CA、香港、KR、SG待定
The acquisition of this new patent portfolio represents the culmination of years of research by world renowned scientists and institutions as well as millions of dollars in development costs and further enhances the Company's existing patent and technology base. Xcelerate has issued 10 million shares of its' restricted common stock to HS Pharmaceuticals for these assets. The relevant agreement also provides for a profit-sharing arrangement based on future earnings of the assets as well as providing a Board seat for one of HS Pharmaceuticals members.
收购这一新的专利组合代表着世界知名科学家和机构多年来的研究成果以及数百万美元的开发成本,并进一步增强了公司现有的专利和技术基础。Xcelerate已向HS PharmPharmticals发行了1,000万股限制性普通股,以换取这些资产。相关协议还规定了基于资产未来收益的利润分享安排,并为HS PharmPharmticals的一名成员提供了董事会席位。
About Xcelerate, Inc.
关于Xcelerate公司
Xcelerate is a start-up, development stage company that has assembled an Advisory Board of internationally renowned translational clinicians and engineers to assist the Company in identifying and acquiring cutting-edge engineering technological advancements and intellectual property, most of which does not have immediately obvious applications to medical technology and clinical care. The Company goal is to acquire innovation at the engineering/patent level and develop med tech and clinical care applications.
Xcelerate是一家初创、处于发展阶段的公司,它组建了一个由国际知名的翻译临床医生和工程师组成的顾问委员会,以帮助公司识别和获取尖端工程技术进步和知识产权,其中大多数技术进步和知识产权在医疗技术和临床护理方面没有立即明显的应用。该公司的目标是在工程/专利层面获得创新,并开发医疗技术和临床护理应用。
Xcelerate has also recently acquired a 51% ownership interest in AfiyaSasa Africa, LLC a start-up medical technology and virtual health company, recently founded by Dr. Dilan Ellegala and Doyle Word. This technology is centered around patented and patent pending software that uses and incorporates artificial intelligence ("AI") and Augmented Reality ("AR") licensed from AdviNOW.
Xcelerate最近还收购了AfiyaSasa Africa LLC 51%的股权,AfiyaSasa Africa LLC是一家初创医疗技术和虚拟健康公司,最近由Dilan ElLegala博士和Doyle Word创建。这项技术以专利和正在申请专利的软件为中心,这些软件使用并整合了AdviNOW授权的人工智能(AI)和增强现实(AR)。
For more information, visit the company's website at
欲了解更多信息,请访问该公司网站:
SAFE HARBOR
安全港
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and actual results may differ materially from those projected in forward-looking statements resulting from various factors.
本新闻稿可能包含经修订的1934年证券交易法(“交易法”)第21E节所指的前瞻性信息,包括与公司、其董事或高级管理人员在以下方面的意图、信念或当前预期有关的所有不是历史事实的陈述:(1)公司的融资计划;(2)影响公司财务状况或经营结果的趋势;(3)公司的增长战略和经营战略;以及(4)宣布和支付股息。“可能”、“将”、“将”、“预期”、“估计”、“预期”、“相信”、“打算”以及类似的表述及其变体旨在识别前瞻性陈述。请投资者注意,任何这样的前瞻性陈述都不是对未来业绩的保证,涉及风险和不确定因素,其中许多风险和不确定因素是公司无法控制的,由于各种因素,实际结果可能与前瞻性陈述中所预测的大不相同。
Xcelerate Contact
加速触点
Info@Xcelerate.Global
邮箱:Info@Xcelerate.Global
SOURCE: Xcelerate, Inc.
资料来源:Xcelerate公司
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧